Skip to main content
Top
Published in: Current Treatment Options in Neurology 8/2015

01-08-2015 | Headache (JR Couch, Section Editor)

Update on Medication-Overuse Headache and Its Treatment

Authors: Maria Adele Giamberardino, MD, Dimos-Dimitrios Mitsikostas, MD, Paolo Martelletti, MD

Published in: Current Treatment Options in Neurology | Issue 8/2015

Login to get access

Opinion statement

Medication-overuse headache—i.e., a too-frequent consumption of acute headache medications leading to increased headache frequency and reduced effectiveness of acute and preventive treatments—is a serious medical condition whose pathophysiology still remains incompletely known, which is reflected into a lack of mechanism-based treatments. The first mandatory step in the therapeutic strategy remains withdrawal of the abused drug, preferably abrupt, in concomitance with a detoxification pharmacological regimen to lessen withdrawal symptoms. Intravenous hydration, antiemetics, corticosteroids (prednisone), tranquilizers (benzodiazepine), neuroleptics, and rescue medication (another analgesic than the overused) should be delivered in various combinations, on an inpatient (hospitalization and day hospital) basis or outpatient basis, depending on the characteristics of the specific patient and type of overuse. Inpatient withdrawal should be preferred in barbiturate and opioid overuse, in concomitant depression, or, in general, in patients who have difficulty in stopping the overused medication as outpatients. In contrast, in overuse limited to simple analgesics in highly motivated patients, without high levels of depression and/or anxiety, home detoxification should be chosen. Re-prophylaxis should immediately follow detoxification, ideally with local injections of onabotulinumtoxinA every 3 months or topiramate orally for at least 3 months. Adequate information to patients about the risks of a too-frequent consumption of symptomatic headache medications is essential and should constantly parallel treatment to help preventing relapse after detoxification and re-prophylaxis.
Literature
1.
go back to reference Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–7.PubMedCrossRef Martelletti P. The therapeutic armamentarium in migraine is quite elderly. Expert Opin Drug Metab Toxicol. 2015;11:175–7.PubMedCrossRef
2.
go back to reference Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20:137–47.PubMedCrossRef Giamberardino MA, Martelletti P. Emerging drugs for migraine treatment. Expert Opin Emerg Drugs. 2015;20:137–47.PubMedCrossRef
3.
go back to reference Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015. doi:10.1016/S0140-6736(15)60692-4. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015. doi:10.​1016/​S0140-6736(15)60692-4.
4.
go back to reference Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain 2015;16:58. doi:10.1186/s10194-015-0544-2. Steiner TJ, Birbeck GL, Jensen RH, Katsarava Z, Stovner LJ, Martelletti P. Headache disorders are third cause of disability worldwide. J Headache Pain 2015;16:58. doi:10.​1186/​s10194-015-0544-2.
5.
go back to reference Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17:393–406.PubMedCrossRef Lionetto L, Negro A, Palmisani S, Gentile G, Del Fiore MR, Mercieri M, et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17:393–406.PubMedCrossRef
6.••
go back to reference Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5:87–99. Comprehensive overview of the major aspects of MOH according to recent criteria.PubMedCentralPubMedCrossRef Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5:87–99. Comprehensive overview of the major aspects of MOH according to recent criteria.PubMedCentralPubMedCrossRef
8.
go back to reference Westergaard ML, Glümer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain. 2014;155:2005–13.PubMedCrossRef Westergaard ML, Glümer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain. 2014;155:2005–13.PubMedCrossRef
9.
go back to reference Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34:409–25.PubMedCrossRef Westergaard ML, Hansen EH, Glumer C, Olesen J, Jensen RH. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34:409–25.PubMedCrossRef
10.
go back to reference Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain. 2010;11:151–6.PubMedCentralPubMedCrossRef Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P. Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain. 2010;11:151–6.PubMedCentralPubMedCrossRef
11.
go back to reference Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. 2010;11:431–5.PubMedCentralPubMedCrossRef Gentile G, Borro M, Lala N, Missori S, Simmaco M, Martelletti P. Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain. 2010;11:431–5.PubMedCentralPubMedCrossRef
13.
go back to reference Paemeleire K, Crevits L, Goadsby PJ, Kaube H. Practical management of medication-overuse headache. Acta Neurol Belg. 2006;106:43–51.PubMed Paemeleire K, Crevits L, Goadsby PJ, Kaube H. Practical management of medication-overuse headache. Acta Neurol Belg. 2006;106:43–51.PubMed
14.
go back to reference Mazer-Amirshahi M, Dewey K, Mullins PM, van den Anker J, Pines JM, Perrone J, et al. Trends in opioid analgesic use for headaches in US emergency departments. Am J Emerg Med. 2014;32:1068–73.PubMedCrossRef Mazer-Amirshahi M, Dewey K, Mullins PM, van den Anker J, Pines JM, Perrone J, et al. Trends in opioid analgesic use for headaches in US emergency departments. Am J Emerg Med. 2014;32:1068–73.PubMedCrossRef
15.
go back to reference Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30:610–4.PubMed Andrasik F, Grazzi L, Usai S, Kass S, Bussone G. Disability in chronic migraine with medication overuse: treatment effects through 5 years. Cephalalgia. 2010;30:610–4.PubMed
17.
go back to reference Raggi A, Schiavolin S, Leonardi M, Giovannetti AM, Bussone G, Curone M, et al. Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348:60–6.PubMedCrossRef Raggi A, Schiavolin S, Leonardi M, Giovannetti AM, Bussone G, Curone M, et al. Chronic migraine with medication overuse: association between disability and quality of life measures, and impact of disease on patients’ lives. J Neurol Sci. 2015;348:60–6.PubMedCrossRef
18.
go back to reference Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;8:869–78.PubMedCrossRef Giamberardino MA, Tafuri E, Savini A, Fabrizio A, Affaitati G, Lerza R, et al. Contribution of myofascial trigger points to migraine symptoms. J Pain. 2007;8:869–78.PubMedCrossRef
19.
go back to reference Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;25:185–98.PubMedCrossRef Giamberardino MA, Affaitati G, Fabrizio A, Costantini R. Myofascial pain syndromes and their evaluation. Best Pract Res Clin Rheumatol. 2011;25:185–98.PubMedCrossRef
20.
go back to reference Giamberardino MA, Tana C, Costantini R. Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol. 2014;26:253–9.PubMedCrossRef Giamberardino MA, Tana C, Costantini R. Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol. 2014;26:253–9.PubMedCrossRef
21.
go back to reference Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain. 2009;10:283–90.PubMedCentralPubMedCrossRef Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain. 2009;10:283–90.PubMedCentralPubMedCrossRef
22.
go back to reference Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, et al. Correlation between migraine severity and cholesterol levels. Pain Pract. 2014. doi:10.1111/papr.12229.PubMed Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davì G, et al. Correlation between migraine severity and cholesterol levels. Pain Pract. 2014. doi:10.​1111/​papr.​12229.PubMed
23.
go back to reference Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;14:9.PubMedCentralPubMedCrossRef Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, et al. New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain. 2013;14:9.PubMedCentralPubMedCrossRef
24.
go back to reference Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8 Suppl 7:1–96. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8 Suppl 7:1–96.
25.
go back to reference Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24:1–150. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 2nd edition. Cephalalgia. 2004;24:1–150.
26.
go back to reference Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.CrossRef Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013;33:629–808.CrossRef
27.
go back to reference Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015: 156(6):1003–7 Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. Pain. 2015: 156(6):1003–7
28.•
go back to reference Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ. Pathophysiology of medication overuse headache–an update. Headache. 2014;54:204–10. Comprehensive and critical assessment of pathophysiological hypotheses about MOH generation.PubMedCrossRef Srikiatkhachorn A, le Grand SM, Supornsilpchai W, Storer RJ. Pathophysiology of medication overuse headache–an update. Headache. 2014;54:204–10. Comprehensive and critical assessment of pathophysiological hypotheses about MOH generation.PubMedCrossRef
29.
go back to reference Grande R, Aaseth K, Benth J, Lundqvist C, Russell M. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011;18:129–37.PubMedCrossRef Grande R, Aaseth K, Benth J, Lundqvist C, Russell M. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol. 2011;18:129–37.PubMedCrossRef
30.
go back to reference Rossi P, Di L, Faroni J, Cesarino F, Nappi G, Di Lorenzo C. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097–105.PubMedCrossRef Rossi P, Di L, Faroni J, Cesarino F, Nappi G, Di Lorenzo C. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097–105.PubMedCrossRef
31.
go back to reference Rossi P, Faroni J, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14:10.PubMedCentralPubMedCrossRef Rossi P, Faroni J, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain. 2013;14:10.PubMedCentralPubMedCrossRef
32.•
go back to reference Munksgaard SB, Jensen RH. Medication overuse headache. Headache. 2014;54:1251–7125. Comprehensive update on current treatment options for MOH.PubMedCrossRef Munksgaard SB, Jensen RH. Medication overuse headache. Headache. 2014;54:1251–7125. Comprehensive update on current treatment options for MOH.PubMedCrossRef
33.
go back to reference Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.PubMedCrossRef Obermann M, Katsarava Z. Management of medication-overuse headache. Expert Rev Neurother. 2007;7:1145–55.PubMedCrossRef
34.
go back to reference Diener H, Dodick D, Goadsby P, Bigal M, Bussone G, Silberstein S, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29:1021–7.PubMedCrossRef Diener H, Dodick D, Goadsby P, Bigal M, Bussone G, Silberstein S, et al. Utility of topiramate for the treatment of patients with chronic migraine in the presence or absence of acute medication overuse. Cephalalgia. 2009;29:1021–7.PubMedCrossRef
35.
go back to reference Dodick D, Turkel C, Degryse R, Aurora S, Silberstein S, Lipton R, et al. Onabotulinumtoxin for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the preempt clinical program. Headache. 2010;50:921–36.PubMedCrossRef Dodick D, Turkel C, Degryse R, Aurora S, Silberstein S, Lipton R, et al. Onabotulinumtoxin for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the preempt clinical program. Headache. 2010;50:921–36.PubMedCrossRef
36.
go back to reference Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRef Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803.PubMedCrossRef
37.
go back to reference Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-A in the prophylactic treatment of medication overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427–33.PubMedCentralPubMedCrossRef Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, et al. Botulinum toxin type-A in the prophylactic treatment of medication overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain. 2011;12:427–33.PubMedCentralPubMedCrossRef
38.
go back to reference Munksgaard S, Bendtsen L, Jensen R. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32:834–44.PubMedCrossRef Munksgaard S, Bendtsen L, Jensen R. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012;32:834–44.PubMedCrossRef
39.•
go back to reference Caproni S, Bianchi E, Cupini LM, Corbelli I, Beghi E, Calabresi P, et al. Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. J Headache Pain. 2014;15:88. Interesting paper addressing the crucial issue of predictive factors of response/nonresponse to detoxification in MOH.PubMedCrossRef Caproni S, Bianchi E, Cupini LM, Corbelli I, Beghi E, Calabresi P, et al. Long term headache duration is a factor predicting nonresponse to detoxification and advice in medication overuse headache. J Headache Pain. 2014;15:88. Interesting paper addressing the crucial issue of predictive factors of response/nonresponse to detoxification in MOH.PubMedCrossRef
40.
go back to reference Cargnin S, Viana M, Sances G, Bianchi M, Ghiotto N, Tassorelli C, et al. Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. Eur J Clin Pharmacol. 2014;70:1195–202.PubMedCrossRef Cargnin S, Viana M, Sances G, Bianchi M, Ghiotto N, Tassorelli C, et al. Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. Eur J Clin Pharmacol. 2014;70:1195–202.PubMedCrossRef
41.
go back to reference Trucco M, Meineri P, Ruiz L, Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee (Neurological Hospital Interregional Group for the Study of Headaches). Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain. 2010;6:334–7.CrossRef Trucco M, Meineri P, Ruiz L, Gruppo Neurologico Ospedaliero Interregionale per lo Studio delle Cefalee (Neurological Hospital Interregional Group for the Study of Headaches). Preliminary results of a withdrawal and detoxification therapeutic regimen in patients with probable chronic migraine and probable medication overuse headache. J Headache Pain. 2010;6:334–7.CrossRef
42.
go back to reference Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007;27:1219–25.PubMedCrossRef Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, Pavlovic A, Mijajlovic M, Radojicic A, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia. 2007;27:1219–25.PubMedCrossRef
43.
go back to reference Baumgartner C, Wessely P, Bingöl C, Maly J, Holzner F. Long-term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache. 1989;29:510–4.PubMedCrossRef Baumgartner C, Wessely P, Bingöl C, Maly J, Holzner F. Long-term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache. 1989;29:510–4.PubMedCrossRef
44.
go back to reference Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener H, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5.PubMedCrossRef Katsarava Z, Muessig M, Dzagnidze A, Fritsche G, Diener H, Limmroth V. Medication overuse headache: rates and predictors for relapse in a 4-year prospective study. Cephalalgia. 2005;25:12–5.PubMedCrossRef
45.
go back to reference Hagen K, Albretsen C, Vilming ST, Salvesen R, Grønning M, Helde G, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain. 2011;12:315–22.PubMedCentralPubMedCrossRef Hagen K, Albretsen C, Vilming ST, Salvesen R, Grønning M, Helde G, et al. A 4-year follow-up of patients with medication-overuse headache previously included in a randomized multicentre study. J Headache Pain. 2011;12:315–22.PubMedCentralPubMedCrossRef
46.
go back to reference Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229–35.PubMedCrossRef Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol. 2001;45:229–35.PubMedCrossRef
47.
go back to reference Katsarava Z, Limmroth V, Finke M, Diener H, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective Study. Neurology. 2003;60:1682–3.PubMedCrossRef Katsarava Z, Limmroth V, Finke M, Diener H, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective Study. Neurology. 2003;60:1682–3.PubMedCrossRef
48.
go back to reference Grazzi L, Andrasik F, D’Amico D, Usai S, Kass S, Bussone G. Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up. Headache. 2004;44:678–83.PubMedCrossRef Grazzi L, Andrasik F, D’Amico D, Usai S, Kass S, Bussone G. Disability in chronic migraine patients with medication overuse: treatment effects at 1-year follow-up. Headache. 2004;44:678–83.PubMedCrossRef
49.
go back to reference Boe M, Salvesen R, Mygland A. Chronic daily headache with medication overuse: a randomized follow-up by neurologist or PCP. Cephalalgia. 2009;29:855–63.PubMedCrossRef Boe M, Salvesen R, Mygland A. Chronic daily headache with medication overuse: a randomized follow-up by neurologist or PCP. Cephalalgia. 2009;29:855–63.PubMedCrossRef
50.
go back to reference Boe M, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol. 2009;16:705–12.PubMedCrossRef Boe M, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol. 2009;16:705–12.PubMedCrossRef
51.
go back to reference Rossi P, Faroni J, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196–200.PubMedCrossRef Rossi P, Faroni J, Nappi G. Medication overuse headache: predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia. 2008;28:1196–200.PubMedCrossRef
53.
go back to reference Fritsche G, Frettloh J, Huppe M, Dlugaj M, Matatko N, Gaul C, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151:404–13.PubMedCrossRef Fritsche G, Frettloh J, Huppe M, Dlugaj M, Matatko N, Gaul C, et al. Prevention of medication overuse in patients with migraine. Pain. 2010;151:404–13.PubMedCrossRef
54.
go back to reference Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia. 2000;20:107–13.PubMedCrossRef Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia. 2000;20:107–13.PubMedCrossRef
55.
go back to reference Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone versus placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152–6.PubMed Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone versus placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152–6.PubMed
56.
go back to reference Farinelli I, Dionisi I, Martelletti P. Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med. 2011;6:23–8.PubMedCrossRef Farinelli I, Dionisi I, Martelletti P. Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse? Intern Emerg Med. 2011;6:23–8.PubMedCrossRef
57.
go back to reference Boe M, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache. Neurology. 2007;69:26–31.PubMedCrossRef Boe M, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache. Neurology. 2007;69:26–31.PubMedCrossRef
58.
go back to reference Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33:202–7.PubMedCrossRef Rabe K, Pageler L, Gaul C, Lampl C, Kraya T, Foerderreuther S, et al. Prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2013;33:202–7.PubMedCrossRef
59.
go back to reference Taghdiri F, Togha M, Razeghi Jahromi S, Paknejad SM. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015;55:128–35.PubMedCrossRef Taghdiri F, Togha M, Razeghi Jahromi S, Paknejad SM. Celecoxib vs prednisone for the treatment of withdrawal headache in patients with medication overuse headache: a randomized, double-blind clinical trial. Headache. 2015;55:128–35.PubMedCrossRef
60.
go back to reference Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci. 2010;31:S175–7.PubMedCrossRef Valguarnera F, Tanganelli P. The efficacy of withdrawal therapy in subjects with chronic daily headache and medication overuse following prophylaxis with topiramate and amitriptyline. Neurol Sci. 2010;31:S175–7.PubMedCrossRef
61.
go back to reference Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache. 2008;48:1087–95.PubMedCrossRef Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, et al. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache. 2008;48:1087–95.PubMedCrossRef
62.
go back to reference Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.PubMedCrossRef Diener H, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P, et al. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23.PubMedCrossRef
63.
go back to reference Roceanu A, Antochi F, Bajenaru O. Chronic migraine – new treatment options MAEDICA. J Clin Med. 2014;9:401–4. Roceanu A, Antochi F, Bajenaru O. Chronic migraine – new treatment options MAEDICA. J Clin Med. 2014;9:401–4.
64.
go back to reference Grazzi L, Usai S. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurol Sci. 2014;35 Suppl 1:37–9.PubMedCrossRef Grazzi L, Usai S. Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse. Neurol Sci. 2014;35 Suppl 1:37–9.PubMedCrossRef
65.
go back to reference Mathew NT, Jaffri SFA. A double-blind comparison of OnabotulinumtoxinA (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49:1466–78.PubMedCrossRef Mathew NT, Jaffri SFA. A double-blind comparison of OnabotulinumtoxinA (BOTOX®) and topiramate (TOPAMAX®) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;49:1466–78.PubMedCrossRef
66.
go back to reference Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51:21–32.PubMedCrossRef Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;51:21–32.PubMedCrossRef
67.
go back to reference Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307.PubMedCrossRef Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C. Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45:293–307.PubMedCrossRef
68.
go back to reference Làinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007;14:900–6.PubMedCrossRef Làinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007;14:900–6.PubMedCrossRef
69.
go back to reference Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo controlled trial. Mayo Clin Proc. 2005;80:1126–37.PubMedCrossRef Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo controlled trial. Mayo Clin Proc. 2005;80:1126–37.PubMedCrossRef
70.•
go back to reference Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24:1289–97. Interesting paper evaluating a prophylactic option for MOH.PubMedCrossRef Sarchielli P, Messina P, Cupini LM, Tedeschi G, Di Piero V, Livrea P, et al. Sodium valproate in migraine without aura and medication overuse headache: a randomized controlled trial. Eur Neuropsychopharmacol. 2014;24:1289–97. Interesting paper evaluating a prophylactic option for MOH.PubMedCrossRef
71.
go back to reference Fan W, Lv Y, Ying G, Li W, Zhou J. Pilot study of amitriptyline in the prophylactic treatment of medication-overuse headache: a 1-year follow-up. Pain Med. 2014;15:1803–10.PubMedCrossRef Fan W, Lv Y, Ying G, Li W, Zhou J. Pilot study of amitriptyline in the prophylactic treatment of medication-overuse headache: a 1-year follow-up. Pain Med. 2014;15:1803–10.PubMedCrossRef
72.
go back to reference Couch JR, Lenaerts ME. Medication overuse headache: clinical features, pathogenesis and management. Drug Dev Res. 2007;68:1–12.CrossRef Couch JR, Lenaerts ME. Medication overuse headache: clinical features, pathogenesis and management. Drug Dev Res. 2007;68:1–12.CrossRef
73.
go back to reference Lenaerts ME, Couch JR. Medication overuse headache. Minerva Med. 2007;98:221–31.PubMed Lenaerts ME, Couch JR. Medication overuse headache. Minerva Med. 2007;98:221–31.PubMed
75.
go back to reference Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRef Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010;50:1406–18.PubMedCrossRef
76.
go back to reference Diener H, Dodick D, Aurora S, Turkel C, Degryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the Preempt 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRef Diener H, Dodick D, Aurora S, Turkel C, Degryse R, Lipton R, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the Preempt 2 trial. Cephalalgia. 2010;30:804–14.PubMedCrossRef
77.
go back to reference Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol. 2010;17:1318–25.PubMed Bendtsen L, Evers S, Linde M, Mitsikostas DD, Sandrini G, Schoenen J. EFNS guideline on the treatment of tension-type headache – report of an EFNS task force. Eur J Neurol. 2010;17:1318–25.PubMed
79.
go back to reference Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2:103–22.PubMedCrossRef Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55 Suppl 2:103–22.PubMedCrossRef
80.
go back to reference Rokyta R, Fricová J. Neurostimulation methods in the treatment of chronic pain. Physiol Res. 2012;61 Suppl 2:S23–31.PubMed Rokyta R, Fricová J. Neurostimulation methods in the treatment of chronic pain. Physiol Res. 2012;61 Suppl 2:S23–31.PubMed
81.
go back to reference Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14:86.PubMedCentralPubMedCrossRef Martelletti P, Jensen RH, Antal A, Arcioni R, Brighina F, de Tommaso M, et al. Neuromodulation of chronic headaches: position statement from the European Headache Federation. J Headache Pain. 2013;14:86.PubMedCentralPubMedCrossRef
82.
go back to reference Arcioni R, Palmisani S, Mercieri M, Vano V, Tigano S, Smith T, et al. Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: a prospective, open-label, exploratory study. Eur J Pain. 2015. doi:10.1002/ejp.692.PubMed Arcioni R, Palmisani S, Mercieri M, Vano V, Tigano S, Smith T, et al. Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: a prospective, open-label, exploratory study. Eur J Pain. 2015. doi:10.​1002/​ejp.​692.PubMed
83.
go back to reference Cicolini G, Palma E, Tafuri E, Sansoni J, Giamberardino MA. Effectiveness of the telephonic-case-management for treatment of headache. A pilot study. Prof Inferm. 2011;64:173–8.PubMed Cicolini G, Palma E, Tafuri E, Sansoni J, Giamberardino MA. Effectiveness of the telephonic-case-management for treatment of headache. A pilot study. Prof Inferm. 2011;64:173–8.PubMed
Metadata
Title
Update on Medication-Overuse Headache and Its Treatment
Authors
Maria Adele Giamberardino, MD
Dimos-Dimitrios Mitsikostas, MD
Paolo Martelletti, MD
Publication date
01-08-2015
Publisher
Springer US
Published in
Current Treatment Options in Neurology / Issue 8/2015
Print ISSN: 1092-8480
Electronic ISSN: 1534-3138
DOI
https://doi.org/10.1007/s11940-015-0368-z

Other articles of this Issue 8/2015

Current Treatment Options in Neurology 8/2015 Go to the issue

Dementia (E McDade, Section Editor)

Treatment of Vascular Cognitive Impairment

Dementia (E McDade, Section Editor)

Treatment of Primary Progressive Aphasia

Sleep Disorders (S Chokroverty, Section Editor)

Treatment of Sleep-Related Eating Disorder